Dr. Patrick D. Lyden is a Neurology specialist affiliated with Marina del Rey Hospital. He has received his medical degree from the Baylor College of Medicine and has completed the residency at the University of California, San Diego School of Medicine. He has done extensive research on the subject of translational stroke and has published numerous papers on various subjects regarding the science of Neurology. His work has been recognized with many awards and he is a member of various associations such as the American Heart Association, American Neurology Association and the Society for Neuroscience.

Insurance Accepted

  • Aetna Choice POS II
  • Cigna
  • First Health PPO
  • Great West PPO
  • HealthNet
  • Multiplan PPO
  • United Healthcare

Languages Spoken

  • English

Education & Training

Medical Degree

Baylor College of Medicine

Internship(s)

Mercy Hospital and Medical Center

Residency(ies)

University of California, San Diego School of Medicine

Fellowship(s)

University of California, San Diego School of Medicine



Memberships & Affiliations

  • American Heart Association American Heart Association
  • Publications & Media

    • Differential Expression of Vascular Endothelial Growth Factor-A165 Isoforms Between Intracranial Atherosclerosis and Moyamoya Disease.

    • Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data.

    • Differential effects of hypothermia on neurovascular unit determine protective or toxic results: Toward optimized therapeutic hypothermia.

    • Acute neuropathological consequences of short-term mechanical ventilation in wild-type and Alzheimer's disease mice.

    • Neuroprotection and vasculoprotection using genetically targeted protease-ligands.

    • β-adrenergic receptor inhibition affects cerebral glucose metabolism, motor performance, and inflammatory response after traumatic brain injury.

    • Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH.

    • Multimodal neuroprotective therapy with induced hypothermia after ischemic stroke.

    • Protease activated receptor-1 mediates cytotoxicity during ischemia using in vivo and in vitro models.

    • Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats.

    • Concurrent middle cerebral artery occlusion and intra-arterial drug infusion via ipsilateral common carotid artery catheter in the rat.

    • Hemorrhagic transformation during thrombolytic therapy and reperfusion: effects of age, blood pressure, and matrix metalloproteinases.

    • Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models.

    • PHLPP1 gene deletion protects the brain from ischemic injury.

    • Thrombin activity associated with neuronal damage during acute focal ischemia.